




RealRate

PHARMACEUTICAL 2017

Oncternal Therapeutics Inc.
Rank 204 of 313



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2017

Oncternal Therapeutics Inc. Rank 204 of 313

The relative strengths and weaknesses of Oncternal Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncternal Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 285% points. The greatest weakness of Oncternal Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 307% points.

The company's Economic Capital Ratio, given in the ranking table, is -344%, being 73% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	24,298
Cost of Goods Sold	0
Intangible Assets	123
Liabilities, Current	4,611
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	-8,163
Other Liabilities	0
Other Net Income	46
Property and Equipment	81
Research and Development	17,228
Revenues	0
Selling, General and Administrative Expense	8,705

Output Variable	Value in 1000 USD
Assets	24,502
Liabilities	4,611
Expenses	17,770
Stockholders Equity	19,891
Net Income	-17,724
Comprehensive Net Income	-17,724
Economic Capital Ratio	-344%

